HER2 overexpression in metastatic breast cancer: development of therapies

被引：0

作者：

Pivot, X. ^{[1
]}

Jary, M. ^{[1
]}

Dobi, E. ^{[1
]}

Bazan, F. ^{[1
]}

Chaigneau, L. ^{[1
]}

Cals, L. ^{[1
]}

Almotlak, H. ^{[1
]}

Montcuquet, P. ^{[1
]}

Meneveau, N. ^{[1
]}

Villanueva, C. ^{[1
]}

机构：

[1] CHU Besancon, Med Oncol Serv, F-25000 Besancon, France

来源：

ONCOLOGIE | 2012年 / 14卷 / 01期

关键词：

To be confirmed metastatic breast cancer; HER2; New therapies; Monoclonal antibodies; PHASE-II TRIAL; TRASTUZUMAB; PLUS; CAPECITABINE; PERTUZUMAB; LAPATINIB; DOCETAXEL; EFFICACY; SAFETY;

D O I：

10.1007/s10269-011-2106-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Currently, the standard first-line treatment for patients with HER2 overexpression in metastatic breast cancer is trastuzumab in combination with taxane. Where progress of the disease is seen with trastuzumab, lapatinib in combination with capecitabine, or changing to treatment using trastuzumab with capecitabine has demonstrated interesting results. With the aim of further improving results for these patients, a number of new therapies are being evaluated. Combining trastuzumab with other monoclonal antibodies such as pertuzumab and bevacizumab, or with cytotoxins like TDM1, or with anti-mTORs such as everolimus, which targets other signalling pathways used in cell proliferation and survival, has shown promising results and will soon be part of our range of therapies. To cite this journal: Oncologie 14 (2012).

引用

页码：37 / 40

页数：4

共 50 条

[1] Novel therapies for metastatic HER2 positive breast cancer
Cossetti R.J.D.
Gelmon K.A.
Current Breast Cancer Reports, 2013, 5 (4) : 331 - 340
[2] HER2 breast cancer therapies: a review
Murphy, Conleth G.
Modi, Shanu
BIOLOGICS-TARGETS & THERAPY, 2009, 3 : 289 - 301
[3] Evaluating HER2 amplification and overexpression in breast cancer
Bartlett, JMS
Going, JJ
Mallon, EA
Watters, AD
Reeves, JR
Stanton, P
Richmond, J
Donald, B
Ferrier, R
Cooke, TG
JOURNAL OF PATHOLOGY, 2001, 195 (04): : 422 - 428
[4] Estimating scenarios for survival time in patients with HER2 positive, metastatic breast cancer starting HER2 targeted therapies
Vasista, A.
Stockler, M.
West, T.
Wilcken, N.
Kiely, B.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S216 - S216
[5] Efficacy of HER2 inhibitors in metastatic breast cancer by discordance in HER2 amplification status between primary and metastatic breast cancer
Van Raemdonck, E.
Berteloot, P.
Laenen, A.
Han, S.
Van Nieuwenhuysen, E.
Salihi, R.
Concin, N.
Vergote, I.
Floris, G.
Wildiers, H.
Punie, K.
Neven, P.
CANCER RESEARCH, 2019, 79 (04)
[6] Correlation between serum HER2 extracellular domain (HER2 ECD) levels and tumour size in early, advanced and metastatic breast cancer with HER2 overexpression
Makino, H.
Tengan, H.
Tatsuda, K.
Hashidate, H.
Mio, K.
Kiguchi, T.
Yamazaki, M.
EUROPEAN JOURNAL OF CANCER, 2014, 50 : S114 - S115
[7] HER2 amplification and overexpression between primary and liver metastatic breast cancer: Significance and implication
Williams, Casey B.
De, Pradip
Klein, Jessica
Williams, Kirstin Anne
Cyr, Brigitte
Small, Misty
King, Michelle
Carlson, Jennifer
Sun, Yuliang
Young, Brandon Michael
Willis, Scooter
Dey, Nandini
Krie, Amy K.
Leyland-Jones, Brian
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (26)
[8] Incidence and implications of HER2 and hormonal receptor overexpression in newly diagnosed metastatic breast cancer
Penault-Ilorca, F.
Vincent-Salomon, A.
Mathieu, M.
Trillet-Lenoir, V.
Khayat, D.
Marty, M.
EJC SUPPLEMENTS, 2005, 3 (02): : 114 - 115
[9] ESTIMATING SCENARIOS FOR SURVIVAL TIME IN PATIENTS WITH HER2 POSITIVE, METASTATIC BREAST CANCER (MBC) STARTING HER2 TARGETED THERAPIES
Vasista, A.
Stockler, M.
West, T.
Wilcken, N.
Kiely, B.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2015, 11 : 44 - 45
[10] HER2 overexpressing metastatic breast cancer.
Spigel D.R.
Burstein H.J.
Current Treatment Options in Oncology, 2002, 3 (2) : 163 - 174

← 1 2 3 4 5 →